Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px

Product › Details

TheraPEG™ Factor IX

	Next higher product group	factor IX (coagulation factor) (human)
	Status	2012-05-29 development existent
	Organisation	Pro Bono Bio Group plc (PCC)
	Organisation 2	PolyTherics Ltd.
	Group	Abzena (Group)

Record changed: 2023-07-10

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for haemostat

[1] VarmX B.V.. (5/25/23). "Press Release: VarmX Raises €30 Million Series B2 Financing for IND Approval and Preparations for Pivotal Trial". Leiden....
[2] Hemab ApS. (2/21/23). "Press Release: Hemab Therapeutics Announces $135M Series B Financing to Advance First Prophylactic Treatments for Underserved Bleeding and Thrombotic Disorders". Copenhagen & Boston, MA....
[3] VarmX B.V.. (1/31/23). "Press Release: VarmX Appoints Paul Roos as Chief Financial Officer". Leiden....
[4] Thermo Fisher Scientific Inc.. (9/23/21). "Press Release: Thermo Fisher Scientific Opens Biologics Manufacturing Site in Lengnau, Switzerland". Bremen....
[5] Novo Holdings A/S. (12/14/20). "Press Release: Novo Holdings Creates New Rare Bleeding Disorder Company, Hemab". Copenhagen....
[6] VarmX B.V.. (7/8/20). "Press Release: VarmX Raises €32 million in Series B Financing to Develop Innovative Reversal Agent for the Treatment and Prevention of Severe Bleeding in Patients on Oral Anticoagulants". Leiden....
[7] Bayer AG. (8/30/18). "Press Release: Bayer Receives US Approval for Modern Hemophilia A Treatment Jivi with a Step-wise Prophylaxis Dosing Regimen [Not intended for U.S. and UK Media]". Berlin....
[8] VarmX B.V.. (7/2/18). "Press Release: VarmX Raises € 12.5 Million to Develop Modified Blood Coagulation Factor X for Treating Severe Bleeding in Patients Using Anti-Coagulants". Leiden....
[9] Sanofi S.A.. (3/8/18). "Press Release: Sanofi Completes Acquisition of Bioverativ Inc.". Paris....
[10] Catalyst Biosciences, Inc.. (2/26/18). "Press Release: Catalyst Biosciences Announces Manufacturing Agreement with AGC Biologics for Subcutaneous Factor IX Product CB 2679d". South San Francisco, CA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]